×
About 7,684 results

ALLMedicine™ Gastrointestinal Stromal Tumors Center

Research & Reviews  3,657 results

Mutations in ALK and TSC1 in a gastrointestinal stromal tumor: a case report.
https://doi.org/10.1186/s12893-021-01208-0 10.1146/annurev-med-043010-091813 10.1007/s004280000338 10.1007/978-1-4939-7471-9_12 10.1158/1055-9965.EPI-14-1002 10.1016/j.hoc.2008.11.005 10.1001/jamaoncol.2016.0256 10.1038/modpathol.2013.173 10.1309/AJCPPCKGA2QGBJ1R 10.1186/s12967-016-1075-6 10.1186/s13000-020-0926-x 10.1111/his.14133 10.1245/s10434-014-3729-z
BMC Surgery; Song Q, Li G et. al.

Apr 21st, 2021 - Gastrointestinal stromal tumors rarely occur in children, but when they do, their biological behavior and histopathological patterns differ from those of adults. A 13-year-old boy with a gastrointestinal stromal tumor was characterized by a rare g...

Gastrointestinal stromal tumor: a review of current and emerging therapies.
https://doi.org/10.1007/s10555-021-09961-7 10.2217/fon-2016-0192 10.1016/S1470-2045(20)30269-2
Cancer Metastasis Reviews; Al-Share B, Alloghbi A et. al.

Apr 20th, 2021 - Gastrointestinal stromal tumors (GIST) are rare neoplasms arising from the interstitial cell of Cajal in the gastrointestinal tract. Two thirds of GIST in adult patients have c-Kit mutation and smaller fractions have platelet derived growth factor...

Surgical resection of gastric gastrointestinal stromal tumors (GIST) in octogenarians.
https://doi.org/10.1016/j.amjsurg.2021.03.062
American Journal of Surgery; Shannon AB, Song Y et. al.

Apr 19th, 2021 - Localized gastrointestinal stromal tumors (GISTs) are rare tumors typically managed with surgery, but outcomes among octogenarians remain less studied. Octogenarian patients with stage I-III gastric GISTs were identified from the National Cancer D...

PDGFRA Immunohistochemistry Predicts PDGFRA Mutations in Gastrointestinal Stromal Tumors.
https://doi.org/10.1097/PAS.0000000000001720
The American Journal of Surgical Pathology; Papke DJ, Forgó E et. al.

Apr 16th, 2021 - Platelet-derived growth factor receptor A (PDGFRA) is a receptor tyrosine kinase that is activated by mutations in 10% of gastrointestinal stromal tumors (GISTs) and 55% to 70% of inflammatory fibroid polyps. PDGFRA-mutant GISTs are usually epithe...

see more →

Guidelines  11 results

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295840
World Journal of Gastroenterology; Li J, Wang M et. al.

Dec 25th, 2018 - Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or conse...

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, t...
https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy095/5004450
Casali, P. G.

May 27th, 2018 - Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year. This only covers clinically relevant GISTs, since, if investigated, a much higher number of lesions ≤ 1 cm in diameter (mic.

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal str...
https://doi.org/10.1093/annonc/mdu360
Annals of Oncology : Official Journal of the European Soc... Bellera CA, Penel N et. al.

Jul 29th, 2014 - The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-even...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  3,849 results

Mutations in ALK and TSC1 in a gastrointestinal stromal tumor: a case report.
https://doi.org/10.1186/s12893-021-01208-0 10.1146/annurev-med-043010-091813 10.1007/s004280000338 10.1007/978-1-4939-7471-9_12 10.1158/1055-9965.EPI-14-1002 10.1016/j.hoc.2008.11.005 10.1001/jamaoncol.2016.0256 10.1038/modpathol.2013.173 10.1309/AJCPPCKGA2QGBJ1R 10.1186/s12967-016-1075-6 10.1186/s13000-020-0926-x 10.1111/his.14133 10.1245/s10434-014-3729-z
BMC Surgery; Song Q, Li G et. al.

Apr 21st, 2021 - Gastrointestinal stromal tumors rarely occur in children, but when they do, their biological behavior and histopathological patterns differ from those of adults. A 13-year-old boy with a gastrointestinal stromal tumor was characterized by a rare g...

Gastrointestinal stromal tumor: a review of current and emerging therapies.
https://doi.org/10.1007/s10555-021-09961-7 10.2217/fon-2016-0192 10.1016/S1470-2045(20)30269-2
Cancer Metastasis Reviews; Al-Share B, Alloghbi A et. al.

Apr 20th, 2021 - Gastrointestinal stromal tumors (GIST) are rare neoplasms arising from the interstitial cell of Cajal in the gastrointestinal tract. Two thirds of GIST in adult patients have c-Kit mutation and smaller fractions have platelet derived growth factor...

Surgical resection of gastric gastrointestinal stromal tumors (GIST) in octogenarians.
https://doi.org/10.1016/j.amjsurg.2021.03.062
American Journal of Surgery; Shannon AB, Song Y et. al.

Apr 19th, 2021 - Localized gastrointestinal stromal tumors (GISTs) are rare tumors typically managed with surgery, but outcomes among octogenarians remain less studied. Octogenarian patients with stage I-III gastric GISTs were identified from the National Cancer D...

PDGFRA Immunohistochemistry Predicts PDGFRA Mutations in Gastrointestinal Stromal Tumors.
https://doi.org/10.1097/PAS.0000000000001720
The American Journal of Surgical Pathology; Papke DJ, Forgó E et. al.

Apr 16th, 2021 - Platelet-derived growth factor receptor A (PDGFRA) is a receptor tyrosine kinase that is activated by mutations in 10% of gastrointestinal stromal tumors (GISTs) and 55% to 70% of inflammatory fibroid polyps. PDGFRA-mutant GISTs are usually epithe...

see more →

News  161 results

EMA Green Light for Avapritinib for GIST, Acalabrutinib for CLL
https://www.staging.medscape.com/viewarticle/934648

Jul 26th, 2020 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a thumbs up to two new oncology drugs.  The Committee has recommended granting conditional marketing authorization for avapritinib (Ayvakit, Bluepr...

EMA Green Light for Avapritinib for GIST, Acalabrutinib for CLL
https://www.medscape.com/viewarticle/934648

Jul 26th, 2020 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a thumbs up to two new oncology drugs.  The Committee has recommended granting conditional marketing authorization for avapritinib (Ayvakit, Bluepr...

Ripretinib Extends Survival When All Else Fails in Advanced GIST
https://www.medscape.com/viewarticle/933412

Jul 5th, 2020 - NEW YORK (Reuters Health) - Treatment with oral ripretinib significantly prolonged survival in patients with advanced gastrointestinal stromal tumors (GIST) who did not respond or were intolerant to three other tyrosine-kinase inhibitors in the IN...

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...

see more →

Patient Education  4 results see all →